Developing Thermally Stable Dry Powder Vaccine Platforms Via Spray Drying Tailored for Inhalation Delivery

疫苗开发的创新极大地有益于公共卫生，通过追求新的和改进的生物制剂，并通过改变其配方和制造重新设想新的输送途径。这项拟议的研究将推动一个跨学科科学家团队在设计新的热稳定疫苗平台方面取得的最新进展，该平台针对结核病和流感感染，其中温度敏感生物制剂将通过封装在合适的载体中来稳定，从而消除了在储存和运输中昂贵且通常不可用的制冷设备的必要性。拟议的项目汇集了化学工程和生物医学专业知识，以了解和实施工业相关的干燥技术，这些技术将生产热稳定的干粉疫苗，保留其原始液体形式的免疫增强效力，但现在可以在室温下储存3个月而不会损失活性，而液体效力损失发生在不到1周的时间内。在优化的条件下喷雾干燥这些疫苗粉末可以产生一种通过吸入输送到肺部的产品，提高它们对肺传播感染如结核病和流感的有效性，同时避免了在给药前在液体介质中重新配制干燥疫苗的复杂物流。该研究将产生热稳定干粉结核病和流感疫苗的最佳实例，将其物理和生物学特性与人体呼吸系统中颗粒形成和颗粒空气动力学的工程原理联系起来。新的知识将被转移到适当的制药专家为加拿大的公共健康的利益。

Innovations in vaccine development greatly benefit public health, by pursuing new andimproved biologics, and re-envisioning new delivery routes though changes in theirformulation and manufacture. The proposed research will advance recent progress made byan interdisciplinary team of scientists in designing new thermally stable vaccine platformstargeted against tuberculosis and influenza infection, where the temperature sensitivebiologics will be stabilized by encapsulation in suitable carriers, thereby removing thenecessity for costly and often unavailable refrigeration equipment in their storage andtransport. The proposed project brings together chemical engineering and biomedicalexpertise to understand and implement industrially relevant drying techniques that willproduce thermostable dry powder vaccines retaining their immune-boosting potency as seenin their original liquid form, yet now can be stored at room temperature for 3 months withoutloss in activity whereas liquid losses in potency occur in less than 1 week. Spray-drying thesevaccine powders under optimized conditions results in a product designed for delivery to thelung by inhalation, boosting their effectiveness against lung-borne infections like tuberculosisand influenza, while avoiding the complex logistics of re-constituting dried vaccines in liquidmedia prior to administration. The research will produce optimal examples of thermostabledry powder tuberculosis and influenza vaccines, relating their physical and biologicalproperties to engineering principles on particle formation and particle aerodynamics in thehuman respiratory system. The new knowledge will be transferred to appropriatepharmaceutical experts for the benefit of Canadas public health.